Page 8 - கிறிஸ் ரோஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pharmaceutical Market Europe - June 2021 WHEN BEING ALL-INCLUSIVE IS NO LONGER AN OPTION In this month’s issue we look at antimicrobial resistance and the work of the AMR Action Fund. As Henry Skinner, CEO of the AMR Action Fund says in his article on page 16, AMR is a slow-burning global crisis that, over the long term, has the potential to be even more catastrophic than COVID-19, and there is an urgent need to develop next-generation antibiotics to protect global health. In our cover story about patient diversity in clinical trials, we look at why being all-inclusive is no longer an option, but an obligation, and why it’s time to put patient diversity in the spotlight. As Chris Ross says in his article in this month’s issue, ‘out of the 32,000 patients who took part in trials for the 53 novel medicines approved by the FDA in 2020, the majority (75%) were white. Just 8% were black or African American and even fewer (6%) were Asian’. He goes on to say that ‘if the goa

United statesHenry skinnerChris rossAction fundAfrican americanஒன்றுபட்டது மாநிலங்களில்ஹென்றி ஸ்கின்னர்கிறிஸ் ரோஸ்நடவடிக்கை நிதி